221 related articles for article (PubMed ID: 34649362)
1. An evidence mapping and scientometric analysis of the top-100 most cited clinical trials of anti-PD-1/PD-L1 drugs to treat cancers.
Liu M; Gao Y; Yuan Y; Shi S; Wu J; Tian J; Zhang J
Biomed Pharmacother; 2021 Nov; 143():112238. PubMed ID: 34649362
[TBL] [Abstract][Full Text] [Related]
2. Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer.
Gao Y; Shi S; Ma W; Chen J; Cai Y; Ge L; Li L; Wu J; Tian J
Int Immunopharmacol; 2019 Jul; 72():374-384. PubMed ID: 31030093
[TBL] [Abstract][Full Text] [Related]
3. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
[TBL] [Abstract][Full Text] [Related]
4. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.
Patrinely JR; Young AC; Quach H; Williams GR; Ye F; Fan R; Horn L; Beckermann KE; Gillaspie EA; Sosman JA; Friedman DL; Moslehi JJ; Johnson DB
Eur J Cancer; 2020 Aug; 135():211-220. PubMed ID: 32599411
[TBL] [Abstract][Full Text] [Related]
5. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
[TBL] [Abstract][Full Text] [Related]
6. Bibliometric and visualized analysis of the top-100 highly cited articles on immunotherapy for endometrial cancer.
Zheng W; Wu Y; Wang Y; Cheng J; Shen W
Medicine (Baltimore); 2023 Jul; 102(27):e34228. PubMed ID: 37417594
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
8. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
Naidoo J; Wang X; Woo KM; Iyriboz T; Halpenny D; Cunningham J; Chaft JE; Segal NH; Callahan MK; Lesokhin AM; Rosenberg J; Voss MH; Rudin CM; Rizvi H; Hou X; Rodriguez K; Albano M; Gordon RA; Leduc C; Rekhtman N; Harris B; Menzies AM; Guminski AD; Carlino MS; Kong BY; Wolchok JD; Postow MA; Long GV; Hellmann MD
J Clin Oncol; 2017 Mar; 35(7):709-717. PubMed ID: 27646942
[TBL] [Abstract][Full Text] [Related]
9. Precise medicine of programmed cell death-1/programmed cell death 1 ligand 1 inhibitor immunotherapy combined radiotherapy for inoperable advanced lung cancer: A protocol for systematic review and meta-analysis.
Liu G; Lv X; Ding Y; Guo Y
Medicine (Baltimore); 2021 Jun; 100(24):e26367. PubMed ID: 34128893
[TBL] [Abstract][Full Text] [Related]
10. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
11. Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review.
Spagnolo F; Boutros A; Cecchi F; Croce E; Tanda ET; Queirolo P
BMC Cancer; 2021 Apr; 21(1):425. PubMed ID: 33865350
[TBL] [Abstract][Full Text] [Related]
12. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
Shi Y; Duan J; Guan Q; Xue P; Zheng Y
Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer.
Lurain K; Ramaswami R; Yarchoan R; Uldrick TS
Curr HIV/AIDS Rep; 2020 Oct; 17(5):547-556. PubMed ID: 32827111
[TBL] [Abstract][Full Text] [Related]
14. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.
Constantinidou A; Alifieris C; Trafalis DT
Pharmacol Ther; 2019 Feb; 194():84-106. PubMed ID: 30268773
[TBL] [Abstract][Full Text] [Related]
15. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
16. Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis.
Liu X; Guo CY; Tou FF; Wen XM; Kuang YK; Zhu Q; Hu H
Int J Cancer; 2020 Jul; 147(1):116-127. PubMed ID: 31633798
[TBL] [Abstract][Full Text] [Related]
17. The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis.
Li Y; Lv M; Liu J; Ma J; Liang M; Zheng N
Cancer Manag Res; 2021; 13():1383-1393. PubMed ID: 33613031
[TBL] [Abstract][Full Text] [Related]
18. [Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis].
Chen K; Sun B
Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):927-940. PubMed ID: 33203196
[TBL] [Abstract][Full Text] [Related]
19. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
Ye J; Ji X; Dennis PA; Abdullah H; Mukhopadhyay P
Clin Pharmacol Ther; 2020 Dec; 108(6):1274-1288. PubMed ID: 32564368
[TBL] [Abstract][Full Text] [Related]
20. The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Yi K; Zhu Q; Kuang YK; Jiang SC; Hu H
Int Immunopharmacol; 2020 Oct; 87():106852. PubMed ID: 32759049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]